中重度哮喘-话题@MedSci

#中重度哮喘#

6篇内容 | 686人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1940246, encodeId=299619402464e, content=<a href='/topic/show?id=85092258234' target=_blank style='color:#2F92EE;'>#中重度哮喘#</a>, objectTitle=NEJM：患者自主激素吸入方案可降低中重度哮喘患者恶化风险, objectType=article, longId=299892, objectId=1a6829989271, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a6829989271, replyNumber=0, likeNumber=49, createdTime=2022-12-27, rootId=0, userName=ymljack, userId=460849, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a6829989271, moduleTitle=NEJM：患者自主激素吸入方案可降低中重度哮喘患者恶化风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a6829989271)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940244, encodeId=35511940244bf, content=<a href='/topic/show?id=85092258234' target=_blank style='color:#2F92EE;'>#中重度哮喘#</a>, objectTitle=Lancet Respirat Med：Tezepelumab对中重度哮喘患者的气道炎性细胞、重塑、高反应性的影响, objectType=article, longId=214141, objectId=513b21414187, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=513b21414187, replyNumber=0, likeNumber=49, createdTime=2021-09-11, rootId=0, userName=ymljack, userId=460849, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=513b21414187, moduleTitle=Lancet Respirat Med：Tezepelumab对中重度哮喘患者的气道炎性细胞、重塑、高反应性的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=513b21414187)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940245, encodeId=8311194024582, content=<a href='/topic/show?id=85092258234' target=_blank style='color:#2F92EE;'>#中重度哮喘#</a>, objectTitle=NEJM：度匹鲁单抗治疗未控制的中重度哮喘儿童效果分析, objectType=article, longId=221769, objectId=f859221e69eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f859221e69eb, replyNumber=0, likeNumber=0, createdTime=2022-01-22, rootId=0, userName=ymljack, userId=460849, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f859221e69eb, moduleTitle=NEJM：度匹鲁单抗治疗未控制的中重度哮喘儿童效果分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f859221e69eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940243, encodeId=805c19402433e, content=<a href='/topic/show?id=85092258234' target=_blank style='color:#2F92EE;'>#中重度哮喘#</a>, objectTitle=JAMA：3D vs 2D方案用于持续性中重度哮喘的治疗, objectType=article, longId=213144, objectId=872021314433, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=872021314433, replyNumber=0, likeNumber=44, createdTime=2021-06-29, rootId=0, userName=ymljack, userId=460849, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=872021314433, moduleTitle=JAMA：3D vs 2D方案用于持续性中重度哮喘的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=872021314433)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940242, encodeId=1a0119402429b, content=<a href='/topic/show?id=85092258234' target=_blank style='color:#2F92EE;'>#中重度哮喘#</a>, objectTitle=赛诺菲旗下Dupixent获得FDA批准用于中重度哮喘, objectType=article, longId=151494, objectId=a936151494c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a936151494c3, replyNumber=0, likeNumber=36, createdTime=2019-05-09, rootId=0, userName=ymljack, userId=460849, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a936151494c3, moduleTitle=赛诺菲旗下Dupixent获得FDA批准用于中重度哮喘, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a936151494c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940241, encodeId=b91819402418e, content=<a href='/topic/show?id=85092258234' target=_blank style='color:#2F92EE;'>#中重度哮喘#</a>, objectTitle=2018年 ERS：Dupilumab显著改善中重度哮喘和合并症患者的症状, objectType=article, longId=149158, objectId=7a4f149158de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a4f149158de, replyNumber=0, likeNumber=33, createdTime=2019-03-26, rootId=0, userName=ymljack, userId=460849, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a4f149158de, moduleTitle=2018年 ERS：Dupilumab显著改善中重度哮喘和合并症患者的症状, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a4f149158de)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

中重度哮喘

2020-05-29

ymljack (审核中...)

前往app查看评论内容

#中重度哮喘#

NEJM：患者自主激素吸入方案可降低中重度哮喘患者恶化风险

2022-12-27

ymljack (审核中...)

前往app查看评论内容

#中重度哮喘#

Lancet Respirat Med：Tezepelumab对中重度哮喘患者的气道炎性细胞、重塑、高反应性的影响

2021-09-11

ymljack (审核中...)

前往app查看评论内容

#中重度哮喘#

NEJM：度匹鲁单抗治疗未控制的中重度哮喘儿童效果分析

2022-01-22

ymljack (审核中...)

前往app查看评论内容

#中重度哮喘#

JAMA：3D vs 2D方案用于持续性中重度哮喘的治疗

2021-06-29

ymljack (审核中...)

前往app查看评论内容

#中重度哮喘#

赛诺菲旗下Dupixent获得FDA批准用于中重度哮喘

2019-05-09

ymljack (审核中...)

前往app查看评论内容

#中重度哮喘#

2018年 ERS：Dupilumab显著改善中重度哮喘和合并症患者的症状

2019-03-26

科室
- - 订阅+
  - 更多科室
工具
服务